Wet Age-Related Macular Degeneration Clinical Trial
Official title:
A Randomized, Single-blinded, Multicenter, Phase IV Study to Compare Systemic VEGF Protein Dynamics Following Monthly Intravitreal Injections of 0.5 mg Ranibizumab Versus 2 mg Aflibercept Until Study Week 12 in Patients With Neovascular (Wet) Age-related Macular Degeneration
The purpose of the study was to compare the effect of intravitreal injections of ranibizumab and aflibercept on systemic VEGF protein levels in treatment naïve wet neovascular Age-related Macular Degeneration (wAMD) patients in a detailed time course.
A planned study visit schedule was established at the time of baseline visit (day 1) for all patients. Study assessments for patients were performed at screening visit, baseline (day 1), day 2, day 8 (± 1 day to allow for flexibility in scheduling) and as of day 15 through to day 169 at biweekly visits. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00138632 -
Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
| Terminated |
NCT04594681 -
A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration
|
Phase 1 | |
| Completed |
NCT03585556 -
AAVCAGsCD59 for the Treatment of Wet AMD
|
Phase 1 | |
| Completed |
NCT03362190 -
ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
|
Phase 2 | |
| Not yet recruiting |
NCT04564937 -
The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04504123 -
MMP-9 Inhibition for Recalcitrant Wet AMD
|
Phase 2 | |
| Terminated |
NCT02005133 -
A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics
|
N/A | |
| Completed |
NCT01016873 -
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
|
Phase 2 | |
| Completed |
NCT03748784 -
ADVM-022 Intravitreal Gene Therapy for Wet AMD
|
Phase 1 | |
| Recruiting |
NCT04468997 -
The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD)
|
Phase 1 | |
| Completed |
NCT04685369 -
Effectiveness of Anti-VEGF Treatments in Wet AMD in Active Smokers
|
||
| Enrolling by invitation |
NCT04932980 -
Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD
|
N/A | |
| Recruiting |
NCT05297292 -
A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD
|
Phase 2/Phase 3 | |
| Completed |
NCT03939767 -
Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease
|
||
| Completed |
NCT03066258 -
Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial
|
Phase 1/Phase 2 | |
| Terminated |
NCT01086761 -
Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration
|
Phase 1 | |
| Recruiting |
NCT05727397 -
Efficacy and Safety of RC28-E Versus Aflibercept
|
Phase 3 | |
| Completed |
NCT04884399 -
Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD
|
Phase 1 | |
| Completed |
NCT04964089 -
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
|
Phase 3 | |
| Withdrawn |
NCT01339949 -
Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
|
N/A |